2-(3-hydroxy-4-nitro-phenyl)-propionic acid | 62143-77-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 2-(3-hydroxy-4-nitro-phenyl)-propionic acid
• 英文别名: 2-(3-hydroxy-4-nitrophenyl)propanoic acid
• CAS: 62143-77-5
• 化学式: C₉H₉NO₅
• 分子量: 211.174
• InChiKey: GXAUQRYAXGQTDO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(3-hydroxy-4-nitro-phenyl)-propionic acid 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 生成 4-amino-5-hydroxyphenyl-2-methylacetic acid
  参考文献：
  名称：

  一些2-芳基-6-苯并恶唑乙酸衍生物的合成和抗炎活性。

  摘要：

  描述了合成2-芳基-6-取代的苯并恶唑的各种方法。筛选了包括6-甲基衍生物4a，乙胺10和19，乙醇12和14，乙酸和α-甲基乙酸9和16a-f以及乙酸酯11的产品对角叉菜胶的抗炎活性。诱导的大鼠爪水肿试验。一些化合物具有优于苯丁氮酮的活性，并且具有与贝诺沙芬相同的活性。

  DOI：

  10.1021/jm00216a011
• 作为产物：
  描述：

  Ethyl 2-(3-hydroxy-4-nitrophenyl)propanoate 在 sodium hydroxide 、 水 、 溶剂黄146 作用下， 以 乙醇 、 水 为溶剂， 反应 14.0h， 以99.5%的产率得到2-(3-hydroxy-4-nitro-phenyl)-propionic acid
  参考文献：
  名称：

  Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process for Making Them, and Use Thereof for Treating Pain and Other Conditions

  摘要：

  与公式I相对应的辣椒素受体配体化合物：含有这种化合物的药物组合物，生产这种化合物的方法，以及使用这种化合物治疗或抑制疼痛和各种其他疾病或症状的方法。

  公开号：

  US20090156590A1

文献信息

• Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof to Treat Pain and Other Conditions
  申请人：Frank Robert

  公开号：US20110301156A1

  公开（公告）日：2011-12-08

  Vanilloid receptor ligand compounds corresponding to formula I: pharmaceutical compositions containing such compounds, a process for producing such compounds, and methods of using such compounds for treating or inhibiting pain and various other disorders or conditions.

  Vanilloid受体配体化合物I式对应的药物组成物，含有这种化合物的药物组成物，制备这种化合物的过程，以及使用这种化合物治疗或抑制疼痛和各种其他疾病或情况的方法。
• Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions
  申请人：Gruenenthal GmbH

  公开号：US08084484B2

  公开（公告）日：2011-12-27

  Vanilloid receptor ligand compounds corresponding to formula I: pharmaceutical compositions containing such compounds, a process for producing such compounds, and methods of using such compounds for treating or inhibiting pain and various other disorders or conditions.

  公式I所对应的vanilloid受体配体化合物：包含这些化合物的药物组合物，制备这些化合物的过程，以及使用这些化合物治疗或抑制疼痛和各种其他疾病或病况的方法。
• Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof to treat pain and other conditions
  申请人：Frank Robert

  公开号：US08785474B2

  公开（公告）日：2014-07-22

  Vanilloid receptor ligand compounds corresponding to formula I: pharmaceutical compositions containing such compounds, a process for producing such compounds, and methods of using such compounds for treating or inhibiting pain and various other disorders or conditions.

  配方I相应的辣椒素受体配体化合物：含有这种化合物的制药组合物，生产这种化合物的过程，以及使用这种化合物治疗或抑制疼痛和各种其他疾病或症状的方法。
• Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies
  作者：Marco Migliore、Damien Habrant、Oscar Sasso、Clara Albani、Sine Mandrup Bertozzi、Andrea Armirotti、Daniele Piomelli、Rita Scarpelli

  DOI：10.1016/j.ejmech.2015.12.036

  日期：2016.2

  Non-steroidal anti-inflammatory drugs (NSAIDs) exert their pharmacological effects by inhibiting cyclooxygenase (COX)-1 and COX-2. Though widely prescribed for pain and inflammation, these agents have limited utility in chronic diseases due to serious mechanism-based adverse events such as gastrointestinal damage. Concomitant blockade of fatty acid amide hydrolase (FAAH) enhances the therapeutic effects of the NSAIDs while attenuating their propensity to cause gastrointestinal injury. This favorable interaction is attributed to the accumulation of protective FAAH substrates, such as the endocannabinoid anandamide, and suggests that agents simultaneously targeting COX and FAAH might provide an innovative strategy to combat pain and inflammation with reduced side effects. Here, we describe the rational design and structure-active relationship (SAR) properties of the first class of potent multitarget FAAH-COX inhibitors. A focused SAR exploration around the prototype 10r (ARN2508) led to the identification of achiral (18b) as well as racemic (29a-c and 29e) analogs. Absolute configurational assignment and pharmacological evaluation of single enantiomers of 10r are also presented. (S)-(+)-10r is the first highly potent and selective chiral inhibitor of FAAH-COX with marked in vivo activity, and represents a promising lead to discover novel analgesics and anti-inflammatory drugs. (C) 2015 Elsevier Masson SAS. All rights reserved.
• DUNWELL D. W.; EVANS D., J. MED. CHEM. <JMCM-AR>, 1977, 20, NO 6, 797-801
  作者：DUNWELL D. W.、 EVANS D.

  DOI：——

  日期：——